Your browser is no longer supported. Please, upgrade your browser.
SGEN Seagen Inc. daily Stock Chart
SGEN [NASD]
Seagen Inc.
Index- P/E- EPS (ttm)-1.50 Insider Own0.90% Shs Outstand173.41M Perf Week-6.56%
Market Cap35.07B Forward P/E2152.39 EPS next Y0.09 Insider Trans-67.20% Shs Float172.78M Perf Month10.73%
Income-255.70M PEG- EPS next Q0.46 Inst Own93.90% Short Float2.52% Perf Quarter11.98%
Sales1.02B P/S34.53 EPS this Y32.10% Inst Trans-0.12% Short Ratio4.50 Perf Half Y42.44%
Book/sh10.46 P/B18.93 EPS next Y115.00% ROA-11.90% Target Price193.44 Perf Year96.27%
Cash/sh5.06 P/C39.15 EPS next 5Y- ROE-14.10% 52W Range90.57 - 213.94 Perf YTD73.31%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-11.80% 52W High-7.44% Beta1.15
Dividend %- Quick Ratio4.40 Sales past 5Y26.20% Gross Margin90.10% 52W Low118.64% ATR6.16
Employees1605 Current Ratio4.70 Sales Q/Q27.30% Oper. Margin-32.90% RSI (14)57.12 Volatility2.84% 2.87%
OptionableYes Debt/Eq0.00 EPS Q/Q75.10% Profit Margin-25.20% Rel Volume0.46 Prev Close198.22
ShortableYes LT Debt/Eq0.00 EarningsOct 29 AMC Payout- Avg Volume968.11K Price198.02
Recom2.20 SMA200.85% SMA5013.86% SMA20034.82% Volume444,384 Change-0.10%
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Oct-13-20 01:33PM  
08:00AM  
Oct-12-20 06:45AM  
06:45AM  
Oct-08-20 08:00AM  
Oct-07-20 09:44AM  
Oct-05-20 11:13AM  
Oct-03-20 06:55AM  
Oct-01-20 12:42PM  
Sep-28-20 05:33PM  
Sep-24-20 07:33AM  
Sep-21-20 10:20AM  
Sep-18-20 01:17PM  
12:38PM  
06:45AM  
06:45AM  
Sep-16-20 10:09AM  
09:47AM  
Sep-15-20 12:53PM  
09:51AM  
Sep-14-20 07:01PM  
05:40PM  
04:39PM  
04:34PM  
04:00PM  
03:55PM  
01:41PM  
12:48PM  
11:15AM  
10:30AM  
09:55AM  
09:51AM  
09:45AM  
09:38AM  
08:01AM  
06:45AM  
Sep-09-20 08:41PM  
Sep-03-20 08:00AM  
Sep-02-20 02:12PM  
Aug-29-20 11:32AM  
Aug-28-20 11:52AM  
Aug-27-20 08:10AM  
08:00AM  
Aug-18-20 08:00AM  
Aug-12-20 08:00AM  
Aug-06-20 08:00AM  
Jul-31-20 08:32PM  
11:16AM  
Jul-30-20 05:15PM  
04:02PM  
Jul-28-20 06:23AM  
Jul-24-20 12:10PM  
Jul-23-20 12:33PM  
Jul-19-20 08:58AM  
Jul-12-20 01:20PM  
Jul-09-20 08:00AM  
Jul-06-20 10:28AM  
Jul-03-20 10:03AM  
Jun-30-20 07:41AM  
Jun-29-20 04:30PM  
Jun-23-20 09:00PM  
Jun-22-20 11:00AM  
08:12AM  
Jun-18-20 08:00AM  
Jun-09-20 06:11PM  
Jun-03-20 08:00AM  
May-30-20 11:31AM  
May-29-20 08:00AM  
May-22-20 07:00PM  
May-19-20 01:02PM  
May-15-20 01:20PM  
11:20AM  
May-14-20 08:00AM  
May-13-20 05:12PM  
May-12-20 08:00AM  
May-09-20 02:19PM  
May-08-20 10:39AM  
May-07-20 05:42PM  
May-06-20 11:34AM  
May-05-20 08:00AM  
May-04-20 01:25PM  
11:45AM  
May-01-20 02:30PM  
Apr-30-20 05:15PM  
04:02PM  
11:12AM  
Apr-29-20 12:00PM  
10:05AM  
Apr-28-20 12:11PM  
Apr-24-20 08:00AM  
Apr-23-20 12:32PM  
Apr-22-20 02:20PM  
10:00AM  
Apr-21-20 12:34PM  
Apr-20-20 11:42AM  
07:21AM  
Apr-17-20 02:46PM  
02:27PM  
02:08PM  
Apr-16-20 04:38PM  
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIU JEAN IGC/EVP, Leg AffairsSep 21Option Exercise36.779,954366,01958,642Sep 23 07:28 PM
LIU JEAN IGC/EVP, Leg AffairsSep 14Sale170.0011,6101,973,70048,688Sep 16 06:53 PM
HIMES VAUGHN BChief Technical OfficerSep 09Option Exercise15.468,000123,680194,829Sep 11 06:25 PM
HIMES VAUGHN BChief Technical OfficerSep 09Sale147.558,0001,180,385186,829Sep 11 06:25 PM
SIMPSON TODD EChief Financial OfficerSep 01Sale155.8612,0911,884,512126,276Sep 02 07:24 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale155.693,585558,164186,829Sep 02 07:25 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale155.694,611717,906117,882Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 31Sale155.6914,3512,234,367715,209Sep 02 07:24 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale155.694,187651,892138,367Sep 02 07:24 PM
ROMP CHARLES REVP, CommercialAug 31Sale155.691,133176,40257,942Sep 02 07:25 PM
LIU JEAN IGC/EVP, Leg AffairsAug 31Sale155.693,648567,97260,298Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 21Option Exercise19.4210,299199,984729,560Aug 25 06:35 PM
ROMP CHARLES REVP, CommercialAug 18Sale158.174,027636,94159,075Aug 20 06:26 PM
SIEGALL CLAY BPresident and CEOAug 18Sale158.1727,0604,280,053719,261Aug 20 06:26 PM
SIMPSON TODD EChief Financial OfficerAug 18Sale158.179,2621,464,959142,554Aug 20 06:27 PM
HIMES VAUGHN BChief Technical OfficerAug 18Sale158.178,0541,273,892190,414Aug 20 06:23 PM
LIU JEAN IGC/EVP, Leg AffairsAug 18Sale158.176,8461,082,82363,946Aug 20 06:58 PM
DANSEY ROGER DChief Medical OfficerAug 17Sale157.7945071,006122,493Aug 17 09:40 PM
SIEGALL CLAY BPresident and CEOAug 10Option Exercise12.0028,475341,700729,955Aug 13 06:04 AM
SIEGALL CLAY BPresident and CEOAug 10Sale156.7428,4754,463,263718,339Aug 13 06:04 AM
SIMPSON TODD EChief Financial OfficerAug 03Sale165.7220,0003,314,418143,181Aug 05 07:14 PM
HIMES VAUGHN BChief Technical OfficerJul 17Option Exercise15.468,000123,680199,840Jul 21 07:48 PM
HIMES VAUGHN BChief Technical OfficerJul 17Sale179.428,0001,435,363191,840Jul 21 07:48 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.0028,472341,664734,660Jul 10 06:07 PM
SIEGALL CLAY BPresident and CEOJul 08Sale175.0828,4724,984,808718,339Jul 10 06:07 PM
ROMP CHARLES REVP, CommercialJul 02Sale167.49712119,25355,307Jul 07 06:34 PM
SIMPSON TODD EChief Financial OfficerJul 01Sale167.5811,5731,939,352163,181Jul 02 07:19 PM
LIU JEAN IGC/EVP, Leg AffairsJun 19Sale165.009,8771,629,70563,597Jun 22 07:46 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale158.892,162343,523109,608Jun 19 05:54 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale157.15838131,692111,770Jun 17 07:24 PM
DANSEY ROGER DChief Medical OfficerJun 15Sale157.154,984783,236112,608Jun 17 07:24 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise12.0028,472341,664724,939Jun 10 06:57 PM
SIEGALL CLAY BPresident and CEOJun 08Sale148.7728,4724,235,807718,339Jun 10 06:57 PM
BAKER BROS. ADVISORS LPDirectorMay 15Sale160.001,750,000280,000,0004,082,851May 19 06:03 PM
ROMP CHARLES REVP, CommercialMay 12Option Exercise15.466,942107,32359,517May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 12Sale166.006,9421,152,37252,575May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 08Option Exercise15.466,942107,32359,517May 08 07:54 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.0028,472341,664728,603May 12 07:51 PM
SIEGALL CLAY BPresident and CEOMay 08Sale161.0128,4724,584,311718,339May 12 07:51 PM
BAKER BROS. ADVISORS LPDirectorMay 08Sale158.50500,00079,250,0004,230,539May 08 05:47 PM
ROMP CHARLES REVP, CommercialMay 08Sale163.026,9421,131,66752,575May 08 07:54 PM
DANSEY ROGER DChief Medical OfficerMay 07Option Exercise65.1111,912775,590129,145May 08 07:42 PM
DANSEY ROGER DChief Medical OfficerMay 07Sale164.5011,9121,959,526117,233May 08 07:42 PM
BAKER BROS. ADVISORS LPDirectorMay 07Sale164.41168,24427,660,9474,272,736May 08 05:47 PM
BAKER BROS. ADVISORS LPDirectorMay 06Sale165.05390,07264,379,4734,286,935May 08 05:47 PM
SIEGALL CLAY BPresident and CEOMay 06Sale165.2325,4024,197,062718,339May 07 07:59 PM
WELCH DANIEL GDirectorMay 06Sale164.7915,0002,471,91955,263May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Option Exercise22.1539,059865,277188,563May 06 06:32 PM
AKKARAJU SRINIVASDirectorMay 05Option Exercise20.068,500170,51048,668May 07 07:58 PM
SIEGALL CLAY BPresident and CEOMay 05Sale166.0824,5984,085,341743,741May 07 07:59 PM
WELCH DANIEL GDirectorMay 05Sale166.7320,0003,334,64170,263May 07 07:59 PM
AKKARAJU SRINIVASDirectorMay 05Sale167.268,5001,421,71040,168May 07 07:58 PM
ROMP CHARLES REVP, CommercialMay 05Sale166.185,056840,22652,575May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Sale162.9426,8674,377,596161,696May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Option Exercise12.0014,167170,004175,863May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Sale147.0014,1672,082,556161,696May 06 06:32 PM
LIPPMAN MARC EDirectorMay 04Sale152.031,000152,030130,313May 06 06:19 PM
BAKER BROS. ADVISORS LPDirectorApr 23Option Exercise12.7635,000446,60045,860,149Apr 24 04:25 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.0028,472341,664779,866Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOApr 08Sale120.0128,4723,416,814758,784Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise12.0028,472341,664768,581Mar 11 06:51 PM
SIEGALL CLAY BPresident and CEOMar 09Sale110.0928,4723,134,578758,784Mar 11 06:51 PM
HIMES VAUGHN BChief Technical OfficerMar 06Option Exercise13.518,000108,117193,172Mar 10 08:12 PM
HIMES VAUGHN BChief Technical OfficerMar 06Sale114.918,000919,292188,674Mar 10 08:12 PM
DANSEY ROGER DChief Medical OfficerFeb 18Sale116.3335040,716107,659Feb 20 05:33 PM
SIEGALL CLAY BPresident and CEOFeb 10Option Exercise12.0028,472341,664768,723Feb 12 05:38 PM
SIEGALL CLAY BPresident and CEOFeb 10Sale114.6128,4723,263,110758,784Feb 12 05:38 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale108.5172778,887108,009Feb 05 06:08 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.0028,472341,664785,937Jan 10 07:08 PM
SIEGALL CLAY BPresident and CEOJan 08Sale111.3228,4723,169,433758,784Jan 10 07:08 PM
WELCH DANIEL GDirectorJan 07Option Exercise12.7617,500223,30090,263Jan 09 08:32 PM
DANSEY ROGER DChief Medical OfficerDec 16Sale114.072,000228,140101,146Dec 17 06:48 PM
SIEGALL CLAY BPresident and CEODec 09Option Exercise12.0028,472341,664773,011Dec 10 07:15 PM
SIEGALL CLAY BPresident and CEODec 09Sale114.5628,4723,261,641755,684Dec 10 07:15 PM
HIMES VAUGHN BChief Technical OfficerDec 06Option Exercise12.008,00096,000195,518Dec 10 07:14 PM
HIMES VAUGHN BChief Technical OfficerDec 06Sale117.168,000937,265187,518Dec 10 07:14 PM
DANSEY ROGER DChief Medical OfficerNov 25Option Exercise65.115,000325,550108,146Nov 27 05:32 PM
DANSEY ROGER DChief Medical OfficerNov 25Sale121.485,000607,388103,146Nov 27 05:32 PM
AKKARAJU SRINIVASDirectorNov 21Option Exercise19.0217,500332,85052,726Nov 22 06:35 PM
AKKARAJU SRINIVASDirectorNov 21Sale119.7817,5002,096,12040,168Nov 22 06:35 PM
LIPPMAN MARC EDirectorNov 18Option Exercise15.8935,000556,150148,813Nov 20 06:41 PM
DANSEY ROGER DChief Medical OfficerNov 18Option Exercise65.115,000325,550108,146Nov 20 06:45 PM
DANSEY ROGER DChief Medical OfficerNov 18Sale116.005,000580,000103,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Sale115.8035,0004,053,000131,313Nov 20 06:41 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.0028,472341,664776,483Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEONov 08Sale107.6128,4723,063,816755,684Nov 12 06:24 PM